Genentech’s Enspryng Receives FDA Priority Review for Thyroid Eye Disease, Advancing a Potential New Treatment Option
Genentech, a member of the Roche Group, has announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for Enspryng® (satralizumab) as a treatment for thyroid eye disease (TED). In addition to accepting the application, the FDA has granted the filing Priority Review, underscoring the potential importance of the therapy for patients living with this debilitating autoimmune condition.
The regulatory submission is supported by findings from the global Phase III SatraGO clinical development program, which evaluated the efficacy and safety of Enspryng in adults with moderate-to-severe thyroid eye disease. Results from the two randomized, placebo-controlled studies demonstrated clinically meaningful improvements across multiple measures of disease activity while maintaining a favorable safety profile consistent with previous experience in other approved indications.
Under the Priority Review designation, the FDA is expected to complete its review and issue a decision by October 15, 2026. If approved, Enspryng could become a new treatment option that offers a novel mechanism of action along with the convenience of subcutaneous administration, allowing many patients to receive therapy at home.
FDA Priority Review Highlights the Potential Significance of the Therapy
Priority Review is granted by the FDA to applications for medicines that, if approved, could provide significant improvements in the treatment, diagnosis, or prevention of serious diseases compared with currently available therapies.
The acceptance of the supplemental Biologics License Application marks an important regulatory milestone for Genentech as it seeks to expand the approved uses of Enspryng beyond its current indication in neuromyelitis optica spectrum disorder (NMOSD).
The company submitted the application based on encouraging data generated from the SatraGO-1 and SatraGO-2 Phase III clinical trials. These pivotal studies evaluated whether targeting the inflammatory pathways involved in thyroid eye disease could improve both the clinical manifestations of the disease and patients’ quality of life.
The results from the SatraGO program were first presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) annual meeting in October 2025.
Addressing an Unmet Need in Thyroid Eye Disease
Thyroid eye disease is a chronic autoimmune inflammatory disorder that affects the tissues surrounding the eyes. The condition is most commonly associated with autoimmune thyroid disorders such as Graves’ disease, although it can also occur independently.
Inflammation within the tissues behind the eyes causes swelling of muscles and connective tissue, leading to a range of symptoms that may include:
- Bulging eyes (proptosis)
- Double vision (diplopia)
- Eye pain and pressure
- Redness and inflammation
- Difficulty closing the eyelids
- Vision impairment in severe cases
Beyond the physical symptoms, thyroid eye disease often has a profound emotional and psychological impact because of visible changes in facial appearance and chronic discomfort. Many patients experience reduced quality of life due to impaired vision, cosmetic concerns, and limitations in daily activities.
Although treatment options have expanded in recent years, there remains a need for therapies that provide durable clinical benefit while offering improved convenience and manageable safety profiles.
Novel Mechanism of Action
Enspryng represents a different therapeutic approach compared with existing treatment options for thyroid eye disease.
The medicine is designed to target interleukin-6 (IL-6) receptor signaling, an inflammatory pathway believed to contribute to the autoimmune processes driving thyroid eye disease.
By blocking IL-6 receptor activity, satralizumab aims to reduce inflammation and interrupt immune-mediated tissue damage responsible for many of the disease’s characteristic symptoms.
According to Genentech, this mechanism has the potential to address the underlying biology of the disease rather than simply treating symptoms after they develop.
An additional advantage is that Enspryng is administered as a subcutaneous injection, making home administration possible after appropriate patient training, potentially reducing the need for frequent hospital or infusion-center visits.
Encouraging Results from the SatraGO Clinical Program
The supplemental application is supported by the combined findings from two global Phase III studies:
- SatraGO-1
- SatraGO-2
Both randomized, placebo-controlled trials enrolled patients with moderate-to-severe thyroid eye disease and evaluated improvements across several clinically important measures of disease activity.
Together, the studies demonstrated that Enspryng produced consistent improvements across key symptoms while maintaining a favorable safety profile.
Primary Endpoint: Improvement in Proptosis
One of the defining features of thyroid eye disease is proptosis, or forward displacement of the eye caused by inflammation and swelling of tissues within the orbit.
Reduction of proptosis is considered one of the most meaningful clinical goals because it reflects improvement in the underlying disease process while helping relieve both functional and cosmetic symptoms.
SatraGO-2
The second Phase III study successfully met its primary endpoint.
At Week 24:
- 53% of patients treated with Enspryng achieved a clinically meaningful reduction in proptosis.
- Only 23% of patients receiving placebo achieved the same outcome.
This difference reached statistical significance, demonstrating a clear therapeutic benefit for patients treated with satralizumab.
Supportive Findings from SatraGO-1
The first Phase III trial also demonstrated encouraging results.
In SatraGO-1:
- 49% of patients receiving Enspryng achieved a proptosis response.
- 31% of placebo-treated patients experienced similar improvement.
Although this numerical difference did not achieve statistical significance for the primary endpoint, Genentech stated that the study nevertheless provides valuable confirmatory evidence supporting the therapeutic potential of Enspryng in thyroid eye disease.
Taken together, the totality of evidence from both trials strengthens confidence in the overall clinical benefit observed across the development program.
Improvements Beyond Eye Bulging
In addition to reducing proptosis, Enspryng demonstrated favorable outcomes across several important secondary efficacy endpoints.
Reduction in Disease Activity
Clinical Activity Score (CAS) is widely used to evaluate inflammatory activity in thyroid eye disease.
Across both Phase III studies:
- Between 78% and 90% of patients with active disease experienced reductions in their Clinical Activity Score after treatment with Enspryng.
Lower CAS scores indicate reduced inflammation and improvement in disease activity.
Improvement in Double Vision
Double vision, or diplopia, is another common and disabling symptom experienced by patients with thyroid eye disease.
Across the SatraGO studies:
- Between 44% and 61% of patients with active thyroid eye disease experienced improvements in diplopia following treatment with Enspryng.
Improvement in double vision has the potential to enhance everyday activities such as reading, driving, and walking while reducing overall disability associated with the disease.
Favorable Safety Profile
Safety remains a key consideration for any therapy intended for chronic autoimmune disease.
Genentech reported that no new safety signals emerged during either Phase III study.
Importantly, the safety profile observed in patients with thyroid eye disease was consistent with the established experience for Enspryng in its currently approved indication for neuromyelitis optica spectrum disorder.
This consistency may provide additional reassurance regarding the medicine’s overall benefit-risk profile as regulators evaluate the application.
Company Highlights Potential Benefits
Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development at Genentech, said the FDA’s decision to grant Priority Review represents an important milestone for patients living with thyroid eye disease.
He noted that Enspryng offers a novel mechanism targeting the biology underlying the disease and could provide a new treatment approach that combines meaningful clinical efficacy with a favorable safety profile.
Garraway also emphasized the convenience of subcutaneous administration, which could allow many patients to receive treatment at home rather than requiring infusion-based therapy in clinical settings.
According to the company, combining therapeutic effectiveness with patient convenience has the potential to improve both treatment accessibility and long-term disease management.
With the Priority Review process now underway, Genentech expects the FDA to issue its regulatory decision by October 15, 2026.
If approved, Enspryng would expand beyond its current use in neuromyelitis optica spectrum disorder and become an important new option for adults with moderate-to-severe thyroid eye disease. The approval would also reinforce the growing role of targeted immune therapies in treating autoimmune ophthalmic disorders.
The regulatory review will focus on the complete body of evidence from the SatraGO clinical program, including efficacy, safety, and the overall benefit-risk profile.
Expanding Treatment Possibilities for Patients
The FDA’s acceptance and Priority Review of Genentech’s supplemental Biologics License Application marks a significant step toward broadening treatment options for thyroid eye disease. Supported by positive Phase III clinical data, Enspryng demonstrated meaningful improvements in key clinical outcomes—including reductions in eye bulging, inflammatory activity, and double vision—while maintaining a safety profile consistent with previous clinical experience.
If the FDA grants approval later this year, Enspryng could introduce a differentiated treatment option that combines a novel IL-6 receptor-targeting mechanism, convenient subcutaneous administration, and clinically meaningful efficacy for patients living with this challenging autoimmune disease. Such an approval would represent an important advancement in the management of thyroid eye disease and provide physicians with an additional targeted therapy to address the significant unmet needs of this patient population.
About SatraGO-1 and -2
SatraGO-1 (NCT05987423) and -2 (NCT06106828) are identically designed, Phase III, randomized, placebo-controlled, multicenter studies to determine the efficacy, durability and tolerability of Enspryng for the treatment of adults with active, moderate‑to‑severe TED and chronic inactive TED. The studies enrolled a total of 258 patients from 19 countries. Participants were randomized 1:1 to receive Enspryng or placebo. The primary endpoints were the proportion of participants with active, moderate-to-severe TED who achieved an at least 2 mm reduction in proptosis in the study eye from baseline at week 24.
About thyroid eye disease (TED)
TED, also known as Graves’ ophthalmopathy, is a complex inflammatory autoimmune disease, affecting the area around the eyes and the eyes themselves, that can be sight-threatening, debilitating and disfiguring. The most common symptoms are redness, swelling of the eyes, eyelid retraction, appearance of a stare, bulging of one or both eyes (proptosis), double vision (diplopia) and pain.
TED is a progressive rare disease that affects approximately 155 people out of every 100,000. It most commonly occurs in people with hyperthyroidism, approximately 50% of whom experience at least mild TED, but it can also affect people with hypothyroidism or normal thyroid function.
Despite existing approved treatments for TED, a medical need remains for therapies that are effective, well-tolerated, and have a convenient route of administration.
About Enspryng® (satralizumab)
Enspryng was developed by Chugai, a member of the Roche Group, and is a humanized monoclonal antibody that targets interleukin-6 (IL-6), a key chemical messenger involved in the body’s inflammatory response, receptor activity. Enspryng was designed using novel recycling antibody technology which, compared to conventional technology, allows for sustained IL-6 inhibition by binding strongly and repeatedly to the IL-6 receptor enabling rapid and sustained suppression of inflammatory pathways.
Enspryng is the first and only IL-6 inhibitor treatment currently approved in approximately 90 countries for neuromyelitis optica spectrum disorder (NMOSD), including in the United States and European Union, with a well-established safety profile in over 10,000 patients.
Genentech is committed to developing Enspryng in additional neurological autoimmune and inflammatory diseases that may benefit from inhibition of IL-6 signalling, including autoimmune encephalitis (AIE) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Genentech recently announced positive Phase III results for Enspryng in MOGAD, with regulatory submissions planned this year.
Enspryng has orphan drug designation in the United States and European Union for treatment of NMOSD, and investigational orphan drug designation in the U.S. for MOGAD, anti-NMDA receptor autoimmune encephalitis (anti-NMDAR AIE), and leucine-rich glioma-inactivated 1 autoimmune encephalitis (LGI1 AIE).
